News Headlines

  1. Merus Announces First Patient Dosed In Phase 1 Clinical Trial Of MCLA-158 In Patients With Solid Tumors
    5/24/2018

    Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been dosed in a Phase 1, first-in human clinical trial of MCLA-158 in patients with solid tumors with an initial focus on metastatic colorectal cancer.

  2. U.S. FDA Grants Fast Track Designation For Krystal Biotech’s KB103 For The Treatment Of Dystrophic Epidermolysis Bullosa
    5/24/2018

    Krystal Biotech Inc., (“Krystal”) (NASDAQ:KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare dermatological diseases, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to KB103 for the treatment of dystrophic epidermolysis bullosa (DEB). 

  3. Enrolment Completed In Cynata’s Phase 1 Clinical Trial Of CYP-001 In GvHD
    5/24/2018

    Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the final patient has been treated in Cohort B of its Phase 1 clinical trial of CYP-001, its Cymerus™ mesenchymal stem cell (MSC) product candidate, in steroid-resistant acute graft-versus-host disease (GvHD)

  4. Esperion Announces Third Pivotal Phase 3 Study Of Bempedoic Acid Meets Primary Endpoint
    5/23/2018

    Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today announced positive top-line results from the third of five pivotal Phase 3 studies (Study 3 or 1002-046) expected to be reported this year.

  5. INmune Bio Initiates Phase I Clinical Trial Of INB03
    5/23/2018

    INmune Bio, Inc., an immunotherapy company developing therapies that reprogram the patient’s innate immune system to treat cancer, today announced that it has initiated a Phase 1 clinical trial of its drug candidate INB03™ in patients with advanced solid tumors.

  6. Commencement Of BNC210 Phase 2 Clinical Trial For The Treatment Of Agitation
    5/23/2018

    Bionomics Limited, a global, clinical stage biopharmaceutical company, recently announces that a Phase 2 clinical trial of its therapeutic candidate, BNC210, has commenced in elderly patients with agitation in the hospital setting. The first participant has been recruited into the trial.

  7. Major Cancer Center Further Advances Oncology Research By Integrating Genomic Data Into Medidata's eClinical Platform
    5/23/2018

    Medidata announced that Memorial Sloan Kettering Cancer Center (MSK) is using Rave Omics with Biomarker Discovery for patients with pancreatic cancer, an example of the paradigm shift in clinical trials through the systematic capture of genomic data and the application of artificial intelligence algorithms.

  8. WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office In Japan
    5/22/2018

    WCG™ (WIRB-Copernicus Group®) Clinical Services Division, the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, recently announced the opening of the company’s new office in Tokyo, Japan.

  9. Nabriva Therapeutics Announces Positive Topline Results From Pivotal Phase 3 Clinical Trial Of Oral Lefamulin For The Treatment Of Community-Acquired Bacterial Pneumonia
    5/21/2018

    Nabriva Therapeutics plc (NASDAQ:NBRV) today announced positive topline results from its Lefamulin Evaluation Against Pneumonia (LEAP 2) clinical trial, the second of two global, pivotal Phase 3 clinical trials of lefamulin.

  10. MimiVax Announces Positive Interim Results From Phase II Trial Of SurVaxM Immunotherapy For The Treatment Of Newly Diagnosed Glioblastoma
    5/21/2018

    MimiVax LLC, a clinical-stage biotechnology company developing immunotherapeutics and targeted therapies for cancer treatment, today announced positive interim results from a multicenter Phase II study of SurVaxM in patients with newly diagnosed glioblastoma (nGBM).